股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳市海王英特龍生物技術股份有限公司（於中華人民共和國註冊成立之股份有限公司） 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08329 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 426,000,000 | RMB | | 0.1 | RMB | | 42,600,000 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 426,000,000 | RMB | | 0.1 | RMB ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 持續關連交易 續新海王集團銷售框架協議 獨立董事委員會及獨立股東之獨立財務顧問 續新二零二二年海王集團銷售框架協議 本公司將召開及舉行股東特別大會，以批准新海王集團銷售框架協議及建議銷售上限。海王生物 及其聯繫人將於股東特別大會上就批准新海王集團銷售框架協議及建議銷售上限的決議案放棄投 票。 一般資料 一份載有（其中包括）(a)有關新海王集團銷售框架協議的進一步資料；(b)嘉林資本就新海王集團銷 售框架協議及其項下擬進行交易（包括建議銷售上限）致獨立董事委員會及獨立股東的意見函；及 (c)獨立董事委員會就新海王集團銷售框架協議致獨立股東之函件之通函將盡快寄發予股東。 續新二零二二年海王 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳市海王英特龍生物技術股份有限公司（於中華人民共和國註冊成立之股份有限公司） 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08329 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 426,000,000 | RMB | | 0.1 RMB | | 42,600,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 426,000,000 | RMB | | 0.1 RMB | | 42,600,000 | 本月 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08329 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 426,000,000 | RMB | | 0.1 RMB | | 42,600,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 426,000,000 | RMB | | 0.1 RMB | | 42,600,000 | 本月底法定/註冊股本總額： RMB 42,600,000 FF301 第 1 頁 共 10 頁 v ...

格隆汇8月22日丨海王英特龙(08329.HK)发布公告，非执行董事于琳已获委任为提名委员会成员，自 2025年8月22日起生效。 ...

集团于报告期间的收入较去年同期下降约8.9%，主要是由于部分药品销售季节性波动，及医疗器械收 入有所下降。于集团收入中，约人民币2.51亿元来自于生产和销售药品及医疗器械分部，占集团总收入 约50.61%；约人民币2.45亿元来自于销售及分销药品、保健品分部及医疗器械，占集团总收入约 49.39%。 格隆汇8月22日丨海王英特龙(08329.HK)发布公告，截至2025年6月30日止六个月，实现收入人民币4.96 亿元，同比减少8.9%；毛利为人民币1.58亿元，同比减少18.8%；公司拥有人应占溢利为人民币1906.5 万元，同比减少49.7%；基本每股盈利人民币1.14分。 ...

海王英特龙(08329)发布截至2025年6月30日止6个月中期业绩，该集团取得收入4.96亿元，同比减少 8.92%;公司拥有人应占溢利1906.5万元，同比减少49.71%;每股盈利1.14分。 ...

智通财经APP讯，海王英特龙(08329)发布截至2025年6月30日止6个月中期业绩，该集团取得收入4.96亿 元，同比减少8.92%;公司拥有人应占溢利1906.5万元，同比减少49.71%;每股盈利1.14分。 ...

Report Overview [Company Information and GEM Characteristics](index=1&type=section&id=Company%20Information%20and%20GEM%20Characteristics) The report presents the Company's H1 2025 unaudited interim results, detailing its GEM listing for SMEs with higher investment risk and its core business in pharmaceutical and medical device operations in China - The Company is a joint stock limited company incorporated in the People's Republic of China, with shares listed on the GEM of The Stock Exchange of Hong Kong Limited[1](index=1&type=chunk)[10](index=10&type=chunk) - The GEM market is positioned as a listing platform for small and medium-sized enterprises, carrying **higher investment risks** and potential for greater market volatility[2](index=2&type=chunk) - The Group's principal activities include the development, production, and sale of pharmaceuticals and medical devices, research and development of modern biotechnology, and the purchase and sale of pharmaceuticals, health products, and medical devices, primarily located in China[10](index=10&type=chunk) Financial Statements [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=2&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For H1 2025, the Group's revenue decreased by 8.92% to RMB 495,920'000, gross profit fell by 18.78%, and profit and total comprehensive income dropped by 46.57% to RMB 22,041'000, with basic EPS at RMB 0.0114 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income Key Data (For the six months ended June 30) | Indicator | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 495,920 | 544,504 | -8.92% | | Cost of sales | (337,566) | (349,538) | -3.42% | | Gross profit | 158,354 | 194,966 | -18.78% | | Other income and net other income | 9,191 | 6,703 | 37.12% | | Selling and distribution expenses | (74,120) | (82,983) | -10.68% | | Administrative expenses | (45,050) | (42,379) | 6.30% | | Operating profit | 24,992 | 50,761 | -50.77% | | Profit before tax | 22,746 | 48,292 | -52.90% | | Profit and total comprehensive income for the period | 22,041 | 41,254 | -46.57% | | Profit attributable to owners of the Company | 19,065 | 37,907 | -49.71% | | Basic and diluted earnings per share | RMB 0.0114 | RMB 0.0226 | -49.56% | [Condensed Consolidated Statement of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the Group's total assets less current liabilities decreased by 23.34% to RMB 810,728'000, with net assets falling 24.12% due to reduced time deposits and net current assets Condensed Consolidated Statement of Financial Position Key Data (As at June 30) | Indicator | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Non-current assets | 486,440 | 589,059 | -17.39% | | Current assets | 625,199 | 809,027 | -22.69% | | Current liabilities | 300,911 | 340,423 | -11.61% | | Net current assets | 324,288 | 468,604 | -30.79% | | Total assets less current liabilities | 810,728 | 1,057,663 | -23.34% | | Non-current liabilities | 31,575 | 31,564 | 0.03% | | Net assets | 779,153 | 1,026,099 | -24.12% | | Total equity | 779,153 | 1,026,099 | -24.12% | - Time deposits significantly decreased from **RMB 115,000'000** as of December 31, 2024, to **RMB 20,000'000** as of June 30, 2025[5](index=5&type=chunk) - Bank balances and cash decreased from **RMB 283,424'000** as of December 31, 2024, to **RMB 139,327'000** as of June 30, 2025[5](index=5&type=chunk) [Condensed Consolidated Statement of Changes in Equity](index=5&type=section&id=Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Equity) For H1 2025, total equity attributable to owners of the Company decreased by 24.21% to RMB 707,260'000, primarily due to RMB 244,988'000 in dividends paid to equity holders Condensed Consolidated Statement of Changes in Equity Key Data (For the six months ended June 30) | Indicator | June 30, 2025 (RMB'000) | January 1, 2025 (RMB'000) | June 30, 2024 (RMB'000) | January 1, 2024 (RMB'000) | | :--- | :--- | :--- | :--- | :--- | | Subtotal of equity attributable to owners of the Company | 707,260 | 933,183 | 946,076 | 908,169 | | Non-controlling interests | 71,893 | 92,916 | 111,360 | 108,013 | | Total equity | 779,153 | 1,026,099 | 1,057,436 | 1,016,182 | | Profit and total comprehensive income for the period | 22,041 | N/A | 41,254 | N/A | | Dividends paid to equity holders of the Company | (244,988) | N/A | – | N/A | | Dividends paid to non-controlling interests | (23,999) | N/A | – | N/A | - In H1 2025, dividends of **RMB 244,988'000** were paid to equity holders of the Company, and **RMB 23,999'000** to non-controlling interests[7](index=7&type=chunk)[35](index=35&type=chunk) [Condensed Consolidated Statement of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) For H1 2025, net cash from operating activities significantly increased, and investing activities turned to net inflow due to reduced time deposits; however, large dividend payments led to a substantial net outflow from financing activities, resulting in a net decrease in cash and cash equivalents Condensed Consolidated Statement of Cash Flows Key Data (For the six months ended June 30) | Indicator | 2025 (RMB'000) | 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Net cash generated from operating activities | 41,171 | 21,217 | 94.05% | | Net cash generated from/(used in) investing activities | 89,648 | (79,019) | 213.45% | | Net cash used in financing activities | (274,916) | (2,457) | 11129.30% | | Net decrease in cash and cash equivalents | (144,097) | (60,259) | 139.13% | | Cash and cash equivalents at end of period | 139,327 | 311,947 | -55.49% | - Cash flow from investing activities shifted from a net outflow of **RMB 79,019'000** in the prior year to a net inflow of **RMB 89,648'000** in H1 2025, primarily due to a **RMB 95,000'000** reduction in time deposits[8](index=8&type=chunk) - Net cash outflow from financing activities significantly increased, mainly due to dividend payments of **RMB 244,988'000** to equity holders of the Company and **RMB 23,999'000** to non-controlling interests[9](index=9&type=chunk) Notes to the Financial Statements [Company Information](index=8&type=section&id=Company%20Information) Shenzhen Neptunus Interlong Bio-technique Co., Ltd., incorporated in China and listed on HKEX GEM, primarily develops, produces, sells, and procures pharmaceuticals and medical devices, with the Group controlled by Neptunus Bioengineering and ultimately by Shenzhen Neptunus Holding Group Co., Ltd - The Company's principal activities include the development, production, and sale of pharmaceuticals and medical devices, research and development of modern biotechnology, and the purchase and sale of pharmaceuticals, health products, and medical devices[10](index=10&type=chunk) - The Group is controlled by Shenzhen Neptunus Bioengineering Co., Ltd., listed on the Shenzhen Stock Exchange, with Shenzhen Neptunus Holding Group Co., Ltd. as the ultimate parent company[10](index=10&type=chunk) [Basis of Preparation and Accounting Policies](index=8&type=section&id=Basis%20of%20Preparation%20and%20Accounting%20Policies) The condensed consolidated interim financial statements are prepared in accordance with GEM Listing Rules and HKAS 34, using the historical cost basis, presented in RMB, and authorized for issue - The condensed consolidated interim financial statements are prepared in accordance with the GEM Listing Rules of the Stock Exchange and Hong Kong Accounting Standard 34 "Interim Financial Reporting"[11](index=11&type=chunk) - The financial statements are prepared on a historical cost basis and presented in Renminbi, with all amounts rounded to the nearest thousand[12](index=12&type=chunk) [Adoption of Revised Hong Kong Financial Reporting Standards](index=9&type=section&id=Adoption%20of%20Revised%20Hong%20Kong%20Financial%20Reporting%20Standards) The Group has adopted revised HKFRS effective January 1, 2025, including HKAS 21 (Amendment) "Lack of Exchangeability", with no material impact on current or prior period results or financial position, and expects no significant impact from new standards not yet effective - The Group has adopted HKAS 21 (Amendment) "Lack of Exchangeability" for the first time, with no material impact on the results and financial position for the current and prior periods[14](index=14&type=chunk) - The Board is assessing the potential impact of new Hong Kong Financial Reporting Standards that have been issued but are not yet effective, and does not expect them to have a significant impact on the condensed consolidated financial statements[16](index=16&type=chunk) [Revenue, Other Income and Net Other Income](index=10&type=section&id=Revenue,%20Other%20Income%20and%20Net%20Other%20Income) For H1 2025, the Group's total revenue decreased by 8.92% to RMB 495,920'000, mainly from production and sales of pharmaceuticals/medical devices and sales/distribution of pharmaceuticals/health products, while other income and net other income increased by 37.12% due to reversal of trade and other payables Revenue Composition (For the six months ended June 30) | Revenue Source | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Production and sales of pharmaceuticals and medical devices | 251,003 | 295,150 | -14.96% | | Sales and distribution of pharmaceuticals, health products and medical devices | 244,917 | 249,354 | -1.78% | | **Total Revenue** | **495,920** | **544,504** | **-8.92%** | Other Income and Net Other Income (For the six months ended June 30) | Item | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Interest income from bank deposits | 1,553 | 1,708 | -9.08% | | Reversal of inventory write-down | 201 | 2,001 | -89.91% | | Government grants | 1,679 | 2,612 | -35.72% | | Reversal of trade and other payables | 5,642 | – | N/A | | Others | 116 | 382 | -69.63% | | **Total** | **9,191** | **6,703** | **37.12%** | - The decrease in revenue is primarily due to seasonal fluctuations in certain pharmaceuticals and a decline in medical device revenue[69](index=69&type=chunk) [Segment Reporting](index=11&type=section&id=Segment%20Reporting) The Group manages its operations through two business lines: "Production and Sales of Pharmaceuticals and Medical Devices" and "Sales and Distribution of Pharmaceuticals, Health Products, and Medical Devices," with all operations in China; in H1 2025, external customer revenue for both segments declined, and the "Production and Sales" segment shifted from profit to loss - The Group manages its operations through two business lines: "Production and Sales of Pharmaceuticals and Medical Devices" and "Sales and Distribution of Pharmaceuticals, Health Products, and Medical Devices"[19](index=19&type=chunk)[22](index=22&type=chunk) - All of the Group's operations are conducted in China, thus no geographical segment analysis is provided[20](index=20&type=chunk)[29](index=29&type=chunk) [Segment Results, Assets and Liabilities](index=11&type=section&id=Segment%20Results,%20Assets%20and%20Liabilities) For H1 2025, external customer revenue for "Production and Sales of Pharmaceuticals and Medical Devices" decreased by 14.96% year-on-year, resulting in a loss of RMB 3,562'000, while "Sales and Distribution of Pharmaceuticals, Health Products, and Medical Devices" saw revenue decline by 1.78% and profit by 14.49% to RMB 27,644'000, with total assets for both segments decreasing Segment Revenue and Profit (For the six months ended June 30) | Segment | 2025 External Customer Revenue (RMB'000) | 2024 External Customer Revenue (RMB'000) | YoY Change (%) | 2025 Segment (Loss)/Profit (RMB'000) | 2024 Segment Profit (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Production and sales of pharmaceuticals and medical devices | 251,003 | 295,150 | -14.96% | (3,562) | 17,721 | -120.10% | | Sales and distribution of pharmaceuticals, health products and medical devices | 244,917 | 249,354 | -1.78% | 27,644 | 32,281 | -14.49% | | **Total** | **495,920** | **544,504** | **-8.92%** | **24,082** | **50,002** | **-51.84%** | Segment Assets and Additions to Non-current Assets (As at June 30) | Segment | 2025 Segment Assets (RMB'000) | 2024 Segment Assets (RMB'000) | Change (%) | 2025 Additions to Non-current Segment Assets (RMB'000) | 2024 Additions to Non-current Segment Assets (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Production and sales of pharmaceuticals and medical devices | 737,235 | 895,155 | -17.64% | 7,884 | 20,558 | -61.65% | | Sales and distribution of pharmaceuticals, health products and medical devices | 694,254 | 834,669 | -16.82% | 186 | 8,544 | -97.82% | | **Total** | **1,431,489** | **1,729,824** | **-17.24%** | **8,070** | **29,102** | **-72.27%** | [Reconciliation of Reportable Segment Revenue, Profit Before Tax, Assets and Liabilities](index=13&type=section&id=Reconciliation%20of%20Reportable%20Segment%20Revenue,%20Profit%20Before%20Tax,%20Assets%20and%20Liabilities) This section provides a reconciliation of reportable segment revenue, profit before tax, assets, and liabilities to the consolidated statements, with consolidated revenue at RMB 495,920'000, profit before tax at RMB 22,746'000, total assets at RMB 1,111,639'000, and total liabilities at RMB 332,486'000 Segment to Consolidated Statement Reconciliation (For the six months ended June 30/As at June 30) | Indicator | 2025 (RMB'000) | 2024 (RMB'000) | | :--- | :--- | :--- | | Consolidated Revenue | 495,920 | 544,504 | | Consolidated Profit Before Tax | 22,746 | 48,292 | | Total Consolidated Assets (2025/06/30 vs 2024/12/31) | 1,111,639 | 1,398,086 | | Total Consolidated Liabilities (2025/06/30 vs 2024/12/31) | 332,486 | 371,987 | [Revenue from Major Products and Services](index=15&type=section&id=Revenue%20from%20Major%20Products%20and%20Services) For H1 2025, revenue from sales of pharmaceuticals and health products was RMB 400,411'000, a 5.55% decrease year-on-year, while medical device sales revenue was RMB 95,509'000, a 20.80% decrease year-on-year Revenue from Major Products and Services (For the six months ended June 30) | Product/Service | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Sales of pharmaceuticals and health products | 400,411 | 423,917 | -5.55% | | Sales of medical devices | 95,509 | 120,587 | -20.80% | | **Total** | **495,920** | **544,504** | **-8.92%** | [Geographical Information](index=15&type=section&id=Geographical%20Information) The Group's revenue and non-current assets are entirely derived from and located in China, thus no geographical segment analysis is provided - The Group's revenue and non-current assets are entirely derived from and located in China, thus no geographical segment analysis is provided[29](index=29&type=chunk) [Disaggregation of Revenue from Contracts with Customers](index=15&type=section&id=Disaggregation%20of%20Revenue%20from%20Contracts%20with%20Customers) For H1 2025, revenue from pharmacies accounted for the largest share at RMB 460,644'000, but decreased by 7.84% year-on-year, while revenue from hospitals decreased by 12.89% to RMB 34,325'000 year-on-year Revenue by Customer Category (For the six months ended June 30) | Customer Category | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Hospitals | 34,325 | 39,292 | -12.89% | | Pharmacies | 460,644 | 499,812 | -7.84% | | Others | 951 | 5,400 | -82.39% | | **Total** | **495,920** | **544,504** | **-8.92%** | - Pharmacies are the Group's largest source of revenue, but their revenue decreased by **7.84%** year-on-year[30](index=30&type=chunk) [Profit Before Tax](index=16&type=section&id=Profit%20Before%20Tax) For H1 2025, profit before tax was RMB 22,746'000, a significant decrease of 52.90% year-on-year, with finance costs decreasing, staff costs increasing, and depreciation, amortization, and R&D expenses decreasing Profit Before Tax Components (For the six months ended June 30) | Item | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Finance costs | 2,246 | 2,469 | -9.03% | | Staff costs | 83,948 | 80,645 | 4.10% | | Depreciation of right-of-use assets | 2,314 | 2,593 | -10.79% | | Amortisation of intangible assets | 1,862 | 2,010 | -7.36% | | Depreciation of property, plant and equipment | 10,881 | 11,974 | -9.13% | | Cost of inventories | 333,206 | 338,296 | -1.50% | | Research and development expenses | 16,848 | 18,057 | -6.70% | | Impairment/(reversal) net - trade receivables | (1,304) | 3,197 | -140.79% | | Impairment/(reversal) net - other receivables | 2,446 | 176 | 1289.77% | | Write-down of inventories | 2,485 | 1,597 | 55.60% | | Reversal of inventory write-down | (201) | (2,001) | -89.91% | - The decline in profit before tax is primarily influenced by decreased revenue and gross margin, increased administrative expenses, and a reduction in trade receivables impairment offset by a significant increase in other receivables impairment[70](index=70&type=chunk) [Income Tax Expense](index=17&type=section&id=Income%20Tax%20Expense) For H1 2025, income tax expense was RMB 705'000, a significant decrease of 89.95% year-on-year, mainly due to reduced current China corporate income tax and prior year over-provision adjustments, with three subsidiaries enjoying a 15% preferential tax rate and 200% super deduction for R&D expenses as "High-Tech Enterprises" Income Tax Expense (For the six months ended June 30) | Item | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Current China corporate income tax | 2,367 | 8,378 | -71.74% | | Over-provision in respect of prior year | (995) | – | N/A | | Deferred tax | (667) | (1,340) | -50.15% | | **Total** | **705** | **7,038** | **-89.95%** | - Three subsidiaries are eligible as "High-Tech Enterprises" and enjoy a **15%** preferential tax rate[32](index=32&type=chunk) - The three subsidiaries are eligible for a **200%** super deduction for research and development expenses[33](index=33&type=chunk) [Dividends](index=17&type=section&id=Dividends) For H1 2025, the Company approved and paid total dividends of RMB 244,988'000, including a 2024 final dividend of RMB 0.005 per ordinary share and a special dividend of RMB 0.141 per ordinary share, with no interim dividend recommended for this reporting period Dividends Paid (For the six months ended June 30) | Dividend Type | 2025 (RMB'000) | 2024 (RMB'000) | | :--- | :--- | :--- | | 2024 Final dividend (RMB 0.005 per share) | 8,390 | – | | 2024 Special dividend (RMB 0.141 per share) | 236,598 | – | | **Total** | **244,988** | **–** | - The Board does not recommend the payment of any interim dividend for this reporting period[35](index=35&type=chunk)[78](index=78&type=chunk) [Earnings Per Share](index=18&type=section&id=Earnings%20Per%20Share) For H1 2025, basic earnings per share were RMB 0.0114, a 49.56% decrease from RMB 0.0226 in the prior year, with diluted earnings per share being equal to basic earnings per share due to no potential dilutive effects Earnings Per Share (For the six months ended June 30) | Indicator | 2025 | 2024 | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic earnings per share | RMB 0.0114 | RMB 0.0226 | -49.56% | | Profit attributable to owners of the Company | RMB 19,065'000 | RMB 37,907'000 | -49.71% | | Weighted average number of ordinary shares in issue | 1,678,000,000 shares | 1,678,000,000 shares | 0.00% | - Diluted earnings per share are equal to basic earnings per share, as there are no outstanding ordinary shares with potential dilutive effects[37](index=37&type=chunk) [Property, Plant and Equipment and Right-of-Use Assets](index=18&type=section&id=Property,%20Plant%20and%20Equipment%20and%20Right-of-Use%20Assets) For H1 2025, the Group purchased property, plant and equipment costing approximately RMB 5,371'000, a 54.79% decrease year-on-year, with disposals/write-offs of RMB 1,079'000, and recognized right-of-use assets of RMB 141'000, a significant 97.06% decrease Property, Plant and Equipment and Right-of-Use Assets Movement (For the six months ended June 30) | Item | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Cost of purchases of property, plant and equipment | 5,371 | 11,885 | -54.79% | | Carrying amount of property, plant and equipment disposed of/written off | 1,079 | 2,732 | -60.58% | | Right-of-use assets recognised | 141 | 4,804 | -97.06% | [Trade and Other Receivables](index=18&type=section&id=Trade%20and%20Other%20Receivables) As of June 30, 2025, total trade and other receivables were RMB 303,689'000, a 4.66% decrease from December 31, 2024, with trade receivables (net of allowance) increasing by 8.08% and bills receivable decreasing by 52.56%, alongside significant changes in amounts due from fellow subsidiaries and related companies Trade and Other Receivables (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Trade receivables (net of allowance) | 172,429 | 159,529 | 8.08% | | Bills receivable | 33,849 | 71,328 | -52.56% | | Amounts due from fellow subsidiaries | 11,575 | 24,972 | -53.65% | | Amounts due from related companies | 30,028 | 11,947 | 151.35% | | Other receivables (net of allowance) | 97,411 | 87,676 | 11.11% | | **Total** | **303,689** | **318,533** | **-4.66%** | [Ageing Analysis](index=19&type=section&id=Ageing%20Analysis) As of June 30, 2025, trade receivables due within 3 months constituted the largest portion at RMB 147,099'000, a 46.75% increase from December 31, 2024, while bills receivable due within 3 months were RMB 17,156'000 and those due in 4 to 6 months were RMB 16,693'000 Ageing Analysis of Trade Receivables (As at June 30) | Ageing | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Within 3 months | 147,099 | 100,243 | 46.75% | | 4 to 6 months | 10,507 | 31,018 | -66.13% | | 7 to 12 months | 1,798 | 12,436 | -85.54% | | Over 1 year | 13,025 | 15,832 | -17.60% | | **Total** | **172,429** | **159,529** | **8.08%** | Ageing Analysis of Bills Receivable (As at June 30) | Ageing | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Within 3 months | 17,156 | 25,753 | -33.40% | | 4 to 6 months | 16,693 | 45,575 | -63.37% | | **Total** | **33,849** | **71,328** | **-52.56%** | [Impairment of Trade Receivables](index=20&type=section&id=Impairment%20of%20Trade%20Receivables) As of June 30, 2025, the allowance for expected credit losses on trade receivables was RMB 21,269'000, a 14.37% decrease from December 31, 2024, with RMB 122'000 recognized, RMB 1,426'000 reversed, and RMB 2,265'000 written off during the period Movement in Impairment Allowance for Trade Receivables (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Balance at January 1 | 24,838 | 22,771 | 9.08% | | Expected credit losses recognised during the period | 122 | 4,246 | -97.13% | | Expected credit losses reversed during the period | (1,426) | (2) | 71200.00% | | Amounts written off during the period | (2,265) | (2,177) | 4.04% | | **Balance at end of period** | **21,269** | **24,838** | **-14.37%** | [Impairment of Other Receivables](index=20&type=section&id=Impairment%20of%20Other%20Receivables) As of June 30, 2025, the allowance for expected credit losses on other receivables was RMB 3,945'000, an 82.81% increase from December 31, 2024, with RMB 2,446'000 recognized, no reversals, and RMB 659'000 written off during the period Movement in Impairment Allowance for Other Receivables (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Balance at January 1 | 2,158 | 2,090 | 3.25% | | Expected credit losses recognised during the period | 2,446 | 822 | 197.57% | | Expected credit losses reversed during the period | – | (4) | N/A | | Amounts written off during the period | (659) | (750) | -12.13% | | **Balance at end of period** | **3,945** | **2,158** | **82.81%** | [Trade and Other Payables](index=21&type=section&id=Trade%20and%20Other%20Payables) As of June 30, 2025, total trade and other payables were RMB 188,856'000, a 14.90% decrease from December 31, 2024, with trade payables decreasing by 15.03% and other payables and accrued expenses decreasing by 11.79% Trade and Other Payables (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Trade payables | 121,564 | 143,306 | -15.03% | | Other payables and accrued expenses | 62,870 | 71,285 | -11.79% | | Amounts due to fellow subsidiaries | 3,276 | 6,545 | -49.95% | | Amounts due to intermediate parent company | 285 | 367 | -22.34% | | Amounts due to related companies | 61 | 74 | -17.57% | | Amounts due to ultimate holding company | 800 | 800 | 0.00% | | **Total** | **188,856** | **222,377** | **-14.90%** | [Interest-Bearing Borrowings](index=21&type=section&id=Interest-Bearing%20Borrowings) As of June 30, 2025, the Group's total interest-bearing borrowings were RMB 99,378'000, a 2.30% decrease from December 31, 2024, comprising short-term bank loans of RMB 90,091'000 and other borrowings of RMB 9,287'000, with some secured by properties and guaranteed by non-controlling shareholders and subsidiaries Interest-Bearing Borrowings (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Non-current liabilities - other borrowings | 4,928 | 3,514 | 40.24% | | Current liabilities - short-term bank loans | 90,091 | 94,424 | -4.59% | | Current liabilities - other borrowings | 4,359 | 3,777 | 15.41% | | **Total** | **99,378** | **101,715** | **-2.30%** | - Bank borrowings of **RMB 61,071'000** are secured by the Group's buildings and guaranteed by non-controlling shareholders and several subsidiaries, with effective interest rates ranging from **3.25% to 3.65%**[45](index=45&type=chunk) - Bank borrowings of **RMB 29,020'000** are guaranteed by a non-controlling shareholder of a subsidiary and a subsidiary, with effective interest rates ranging from **3.75% to 4.80%**[45](index=45&type=chunk) [Lease Liabilities](index=23&type=section&id=Lease%20Liabilities) As of June 30, 2025, the present value of lease liabilities was RMB 2,511'000, a 32.43% decrease from December 31, 2024, with RMB 1,924'000 due within one year and RMB 587'000 due after one year; total cash outflow for leases during the period was approximately RMB 2,222'000, a 12.93% decrease year-on-year Lease Liabilities (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Present value of lease liabilities | 2,511 | 3,716 | -32.43% | | Due within one year | 1,924 | 1,949 | -1.30% | | Due in second to fifth years | 587 | 1,767 | -66.78% | | Total cash outflow for leases (For the six months ended June 30) | 2,222 | 2,553 | -12.93% | [Share Capital](index=24&type=section&id=Share%20Capital) As of June 30, 2025, the Company's total registered, issued, and fully paid share capital was RMB 167,800'000, comprising 1,252,000 thousand domestic shares and 426,000 thousand H shares, both with a par value of RMB 0.10, unchanged from January 1, 2025 Share Capital Composition (As at June 30) | Share Type | Number of Shares (thousands) | Amount (RMB'000) | | :--- | :--- | :--- | | Domestic shares (par value RMB 0.10 per share) | 1,252,000 | 125,200 | | H shares (par value RMB 0.10 per share) | 426,000 | 42,600 | | **Total** | **1,678,000** | **167,800** | - As of June 30, 2025, the Company's share capital structure remained unchanged from January 1, 2025[47](index=47&type=chunk) [Commitments](index=24&type=section&id=Commitments) As of June 30, 2025, the Group's capital commitments for contracted but unprovided property, plant and equipment were approximately RMB 1,005'000, an 18.37% increase from December 31, 2024, while short-term lease commitments were RMB 1,313'000, a 9.64% decrease Capital Commitments (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Property, plant and equipment (contracted but not provided for) | 1,005 | 849 | 18.37% | | Short-term lease commitments (within one year) | 1,313 | 1,452 | -9.64% | - The Group has no specific plans for material investments and capital assets[81](index=81&type=chunk) [Significant Related Party Transactions](index=25&type=section&id=Significant%20Related%20Party%20Transactions) The Group engages in various related party transactions with its intermediate parent, immediate parent, fellow subsidiaries, and related companies, primarily involving sales of goods, purchases of finished goods, office rentals, and lease expenses, all conducted on terms comparable to those with third parties in the ordinary course of business - The Group engages in related party transactions with Neptunus Group (intermediate parent company), Neptunus Bioengineering (immediate parent company), and several fellow subsidiaries and related companies, including sales of goods, purchases of finished goods, and office rentals[48](index=48&type=chunk)[49](index=49&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk) - Related party transactions are conducted in the ordinary course of business on terms comparable to those with other third-party suppliers and customers[51](index=51&type=chunk) [Related Party Transactions](index=25&type=section&id=Related%20Party%20Transactions) For H1 2025, total sales of goods to related parties were RMB 28,486'000, a 29.79% decrease year-on-year, while total purchases of finished goods and merchandise from related parties were RMB 26,274'000, a 53.83% decrease year-on-year Key Related Party Transaction Amounts (For the six months ended June 30) | Transaction Nature | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Sales of goods (total) | 28,486 | 40,604 | -29.79% | | Purchases of finished goods/merchandise (total) | 26,274 | 56,907 | -53.83% | | Office rental | 716 | 716 | 0.00% | | Lease expenses | 193 | 148 | 30.41% | - Purchases of finished goods from Shenzhen Neptunus Pharmaceutical Co., Ltd. amounted to **RMB 25,793'000**, a **10.40%** decrease year-on-year[48](index=48&type=chunk) - Purchases of goods from Nanning Neptunus Health Biotechnology Co., Ltd. significantly decreased from **RMB 17,282'000** to **RMB 296'000**[48](index=48&type=chunk) [Outstanding Balances with Related Parties](index=28&type=section&id=Outstanding%20Balances%20with%20Related%20Parties) As of June 30, 2025, total amounts due from related parties were RMB 41,854'000, a 12.59% increase from December 31, 2024, while total amounts due to related parties were RMB 4,422'000, a 43.21% decrease, with all balances unsecured, interest-free, and repayable on demand Outstanding Balances with Related Parties (As at June 30) | Item | June 30, 2025 (RMB'000) | December 31, 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Total amounts due from related parties | 41,854 | 37,170 | 12.59% | | Total amounts due to related parties | 4,422 | 7,786 | -43.21% | | Trade nature amounts due from related parties | 41,531 | 36,850 | 12.70% | | Trade nature amounts due to related parties | 3,337 | 6,619 | -49.59% | - Among trade nature amounts due from related parties, those due within 3 months accounted for the largest portion at **RMB 24,825'000**[59](index=59&type=chunk) - All related party balances are unsecured, interest-free, and repayable on demand[57](index=57&type=chunk) [Key Management Personnel Compensation](index=32&type=section&id=Key%20Management%20Personnel%20Compensation) For H1 2025, total key management personnel compensation was RMB 2,778'000, an 8.69% increase year-on-year, primarily comprising short-term employee benefits and post-employment benefits Key Management Personnel Compensation (For the six months ended June 30) | Item | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Short-term employee benefits | 2,634 | 2,435 | 8.17% | | Post-employment benefits | 144 | 121 | 19.01% | | **Total** | **2,778** | **2,556** | **8.69%** | Management Discussion and Analysis [Business Review](index=33&type=section&id=Business%20Review) The Group primarily engages in pharmaceutical and medical device R&D, production, sales, and trading in China, covering various therapeutic areas; during the period, some business segments declined due to new medical insurance reform policies and rising procurement costs, but the Group actively adjusted sales strategies, optimized product structure, and strengthened medical device expansion and sales network development - The Group primarily engages in pharmaceutical and medical device research and development, production, and sales, as well as the procurement and sales of pharmaceuticals and health food in China, covering therapeutic areas such as oncology, cardiovascular, respiratory, digestive, and mental illnesses[61](index=61&type=chunk) - New medical insurance reform policies adversely affected retail pharmacy sales, consequently impacting the procurement and sales business of pharmaceuticals and health food[66](index=66&type=chunk) - The Group actively adjusted its sales strategies, focusing on key product sales, vigorously developing the health food market, and increasing product promotion through self-media[66](index=66&type=chunk) [R&D, Production and Sales of Pharmaceuticals and Medical Devices](index=33&type=section&id=R%26D,%20Production%20and%20Sales%20of%20Pharmaceuticals%20and%20Medical%20Devices) The Group operates two pharmaceutical production bases in Fuzhou and Beijing, holding 505 national drug approval numbers, most in the National Basic Medical Insurance Drug List, and continues to invest in generic drug consistency evaluation and new drug R&D, holding 97 patents with 5 varieties having passed consistency evaluation; during the period, two Fujian pharmaceutical subsidiaries saw performance decline due to rising procurement costs and reduced sales of high-margin products, while the Beijing pharmaceutical subsidiary improved operational quality through capacity expansion, product structure adjustment, and marketing model changes - The Group operates two pharmaceutical production bases in Fuzhou and Beijing, holding **505** national drug approval numbers, most of which are included in the National Basic Medical Insurance Drug List[62](index=62&type=chunk) - The Group holds **97** patents (**31** invention, **13** design, **53** utility model), with **5** varieties having passed consistency evaluation[63](index=63&type=chunk) - Two Fujian pharmaceutical subsidiaries experienced a decline in performance, primarily due to rising procurement costs and reduced sales of high-margin products[64](index=64&type=chunk) - Beijing Neptunus Zhongxin Pharmaceutical Co., Ltd. improved its operational quality through capacity expansion, product structure adjustment, and marketing model changes, striving to turn losses into profits[65](index=65&type=chunk) [Procurement and Sales of Pharmaceuticals, Health Food and Medical Devices](index=35&type=section&id=Procurement%20and%20Sales%20of%20Pharmaceuticals,%20Health%20Food%20and%20Medical%20Devices) The Group primarily distributes its own and the parent company group's pharmaceuticals, medical devices, and health food, including Neptunus Ginkgo Biloba Tablets and Neptunus Golden Zun series; new medical insurance reform policies adversely affected retail pharmacy sales, leading to a decline in this segment's performance, prompting the Group to plan H2 sales strategy adjustments, focusing on key products, vigorously developing the health food market, and strengthening medical institution terminal development to stabilize and grow the business - The Group primarily distributes and sells its own and the parent company group's pharmaceuticals, medical devices, and health food, including Neptunus Ginkgo Biloba Tablets and Neptunus Golden Zun series[66](index=66&type=chunk) - New medical insurance reform policies adversely affected retail pharmacy sales, leading to a decline in this segment's performance compared to the prior year[66](index=66&type=chunk)[68](index=68&type=chunk) - The Group plans to adjust its H2 sales strategy, focusing on key product sales, vigorously developing the health food market, and increasing product promotion through self-media[66](index=66&type=chunk) - Fuzhou Fuyao Pharmaceutical Co., Ltd. achieved significant results in medical device expansion and regional pharmaceutical and medical device agency, and plans to strengthen medical institution terminal development[67](index=67&type=chunk) [Financial Review](index=36&type=section&id=Financial%20Review) For H1 2025, the Group's revenue decreased by 8.92% to RMB 495,920'000, gross margin declined by 4 percentage points to 32%, leading to an 18.78% decrease in gross profit; sales and distribution expenses decreased by 10.68%, administrative expenses increased by 6.30%, and finance costs decreased by 9.03%, resulting in a 46.57% decrease in profit after tax and a 49.71% decrease in profit attributable to owners of the Company Key Financial Indicators Movement (For the six months ended June 30) | Indicator | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 495,920 | 544,504 | -8.92% | | Gross margin | 32% | 36% | -4 percentage points | | Gross profit | 158,354 | 194,966 | -18.78% | | Selling and distribution expenses | 74,120 | 82,983 | -10.68% | | Administrative expenses | 45,050 | 42,379 | 6.30% | | Finance costs | 2,246 | 2,469 | -9.03% | | Profit after tax | 22,041 | 41,254 | -46.57% | | Profit attributable to owners of the Company | 19,065 | 37,907 | -49.71% | - The decrease in revenue is primarily due to seasonal fluctuations in certain pharmaceuticals and a decline in medical device revenue[69](index=69&type=chunk) - The decline in gross margin is mainly due to increased procurement costs for certain products and reduced revenue from high-margin products[69](index=69&type=chunk) - The increase in administrative expenses is primarily due to higher staff costs and trademark registration fees[70](index=70&type=chunk) [Liquidity and Financial Resources](index=37&type=section&id=Liquidity%20and%20Financial%20Resources) The Group primarily funds its operations and investing activities through internal financial resources and bank borrowings; as of June 30, 2025, short-term bank borrowings were RMB 90,091'000, with some bank financing secured by properties, and the Group faces minimal foreign exchange risk, currently not using financial instruments for hedging, while the asset-liability ratio increased to 42.67% - The Group generally funds its operating and investing activities through internal financial resources and bank borrowings[71](index=71&type=chunk) - As of June 30, 2025, short-term bank borrowings amounted to **RMB 90,091'000**[72](index=72&type=chunk) - Utilized bank financing of **RMB 61,071'000** is secured by properties with a carrying value of approximately **RMB 21,826'000**[73](index=73&type=chunk) - The Group faces minimal foreign exchange risk and currently does not use financial instruments for hedging purposes[74](index=74&type=chunk) Asset-Liability Ratio (As at June 30) | Indicator | June 30, 2025 | December 31, 2024 | Change | | :--- | :--- | :--- | :--- | | Asset-liability ratio | 42.67% | 36.25% | 6.42 percentage points | [Material Investments Held](index=37&type=section&id=Material%20Investments%20Held) Other than as disclosed in this announcement, the Company held no other material investments during the reporting period - During the reporting period, the Company held no other material investments[76](index=76&type=chunk) [Capital Structure](index=37&type=section&id=Capital%20Structure) During the reporting period, the Company's capital structure remained unchanged, with capital comprising its shares and other reserves - During the reporting period, the Company's capital structure remained unchanged, with capital comprising its shares and other reserves[77](index=77&type=chunk) [Interim Dividend](index=37&type=section&id=Interim%20Dividend) The Board does not recommend the payment of any interim dividend for the reporting period - The Board does not recommend the payment of any interim dividend for the reporting period[78](index=78&type=chunk) [Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures](index=37&type=section&id=Material%20Acquisitions%20and%20Disposals%20of%20Subsidiaries,%20Associates%20and%20Joint%20Ventures) During the reporting period, the Group did not undertake any material acquisitions or disposals of subsidiaries, associates, or joint ventures - During the reporting period, the Group did not undertake any material acquisitions or disposals of subsidiaries, associates, or joint ventures[79](index=79&type=chunk) [Contingent Liabilities](index=37&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the Group had no material contingent liabilities - As of June 30, 2025, the Group had no material contingent liabilities[80](index=80&type=chunk) [Future Plans for Material Investments and Capital Assets](index=37&type=section&id=Future%20Plans%20for%20Material%20Investments%20and%20Capital%20Assets) As of June 30, 2025, the Group had no specific plans for material investments and capital assets - As of June 30, 2025, the Group had no specific plans for material investments and capital assets[81](index=81&type=chunk) [No Material Changes](index=38&type=section&id=No%20Material%20Changes) Except as disclosed in this announcement, there have been no material changes in the Group's financial position or business since the publication of the latest annual report for the six months ended June 30, 2025 - Except as disclosed in this announcement, there have been no material changes in the Group's financial position or business since the publication of the latest annual report[82](index=82&type=chunk) [Employees and Remuneration Policy](index=38&type=section&id=Employees%20and%20Remuneration%20Policy) As of June 30, 2025, the Group employed a total of 1,474 staff, with employee costs (including directors' emoluments) of approximately RMB 83,948'000 for the period; the Group determines salaries based on employee performance and experience, offering various benefits, training, and development opportunities - As of June 30, 2025, the Group employed a total of **1,474** staff[83](index=83&type=chunk) Employee Costs (For the six months ended June 30) | Item | 2025 (RMB'000) | 2024 (RMB'000) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Employee costs (including directors' emoluments) | 83,948 | 80,645 | 4.10% | - The Group determines salaries based on employee performance and work experience, offering various benefits, training, and development opportunities[83](index=83&type=chunk)[84](index=84&type=chunk) [Capital Commitments](index=38&type=section&id=Capital%20Commitments) As of June 30, 2025, the Group had contractual commitments for future capital expenditure of approximately RMB 1,005'000 - As of June 30, 2025, the Group had contractual commitments for future capital expenditure of approximately **RMB 1,005'000**[85](index=85&type=chunk) [Directors', Supervisors' and Chief Executive's Interests and Short Positions in Listed Securities](index=38&type=section&id=Directors',%20Supervisors'%20and%20Chief%20Executive's%20Interests%20and%20Short%20Positions%20in%20Listed%20Securities) As of June 30, 2025, directors Mr. Zhang Feng and Ms. Yu Lin beneficially owned approximately 0.05% and 0.03% respectively of the shares in Neptunus Bioengineering, the Company's controlling shareholder; other than this, no directors, supervisors, chief executive, or their associates had any disclosable interests or short positions in the shares, underlying shares, or debentures of the Company or its associated corporations Directors' Long Positions in Shares of Associated Corporations (As at June 30) | Director | Name of Associated Corporation | Number of Shares | Approximate Percentage of Issued Share Capital | | :--- | :--- | :--- | :--- | | Mr. Zhang Feng | Neptunus Bioengineering | 1,331,093 | 0.05% | | Ms. Yu Lin | Neptunus Bioengineering | 900,000 | 0.03% | - Except as disclosed, no directors, supervisors, or chief executive had any disclosable interests or short positions in the shares, underlying shares, or debentures of the Company or its associated corporations[87](index=87&type=chunk) [Share Schemes, Convertible Securities and Warrants](index=39&type=section&id=Share%20Schemes,%20Convertible%20Securities%20and%20Warrants) As of June 30, 2025, neither the Company nor its subsidiaries had adopted any share schemes, nor had they granted any options, convertible securities, warrants, or other similar rights - As of June 30, 2025, neither the Company nor its subsidiaries had adopted any share schemes, nor had they granted any options, convertible securities, warrants, or other similar rights[88](index=88&type=chunk) [Options, Warrants or Convertible Bonds of Directors and Supervisors](index=39&type=section&id=Options,%20Warrants%20or%20Convertible%20Bonds%20of%20Directors%20and%20Supervisors) At no time during the reporting period were any options, warrants, or convertible bonds of the Company, its subsidiaries, or associated corporations granted to any director or supervisor, or their respective spouses or minor children - At no time during the reporting period were any options, warrants, or convertible bonds of the Company, its subsidiaries, or associated corporations granted to any director or supervisor, or their respective spouses or minor children[89](index=89&type=chunk) [Interests of Substantial Shareholders in Shares and Underlying Shares](index=40&type=section&id=Interests%20of%20Substantial%20Shareholders%20in%20Shares%20and%20Underlying%20Shares) As of June 30, 2025, Neptunus Bioengineering directly and indirectly held approximately 73.51% of the Company's issued share capital, making it the controlling shareholder, while Neptunus Group, Neptunus Holdings, and Mr. Zhang Simin are deemed to own approximately 73.51% of the Company's interests through controlled corporations Substantial Shareholders' Long Positions in the Company's Shares (As at June 30) | Substantial Shareholder | Capacity | Number of Domestic Shares Held | Approximate Percentage of the Company's Issued Share Capital | | :--- | :--- | :--- | :--- | | Neptunus Bioengineering | Beneficial owner and interest in controlled corporation | 1,233,464,500 | 73.51% | | Shenzhen Neptunus Group Co., Ltd. | Interest in controlled corporation | 1,233,464,500 | 73.51% | | Neptunus Holdings | Interest in controlled corporation | 1,233,464,500 | 73.51% | | Mr. Zhang Simin | Interest in controlled corporation | 1,233,464,500 | 73.51% | - Neptunus Bioengineering directly and indirectly holds interests in **1,233,464,500** domestic shares of the Company, representing approximately **73.51%** of the issued share capital[93](index=93&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=41&type=section&id=Purchase,%20Sale%20or%20Redemption%20of%20the%20Company's%20Listed%20Securities) During the reporting period, neither the Company nor its subsidiaries purchased, redeemed, or sold any of the Company's listed securities, nor did they hold any treasury shares - During the reporting period, neither the Company nor its subsidiaries purchased, redeemed, or sold any of the Company's listed securities, nor did they sell any treasury shares of the Company[94](index=94&type=chunk) [Competing Interests](index=41&type=section&id=Competing%20Interests) Neptunus Bioengineering, the Company's controlling shareholder, has provided a non-competition undertaking to the Company and complied with it during the reporting period, refraining from directly or indirectly participating in or operating any business that competes with the Company's business - Neptunus Bioengineering, the Company's controlling shareholder, has provided a non-competition undertaking to the Company and complied with it during the reporting period[95](index=95&type=chunk)[96](index=96&type=chunk)[100](index=100&type=chunk) - Pursuant to the non-competition undertaking, Neptunus Bioengineering and its associates shall not directly or indirectly participate in or operate any business that directly or indirectly competes with the Company's business[100](index=100&type=chunk) [Code of Conduct for Securities Transactions by Directors](index=41&type=section&id=Code%20of%20Conduct%20for%20Securities%20Transactions%20by%20Directors) The Company has adopted a code of conduct for directors' securities transactions no less stringent than the GEM Listing Rules' "Required Standard of Dealings," and all directors confirmed compliance after specific inquiry - The Company has adopted a code of conduct for directors' securities transactions that is no less stringent than the "Required Standard of Dealings" set out in the GEM Listing Rules[97](index=97&type=chunk) - Following specific inquiries made to all directors, all directors confirmed their compliance with the code of conduct[97](index=97&type=chunk) [Audit Committee](index=41&type=section&id=Audit%20Committee) The Audit Committee comprises one non-executive director and two independent non-executive directors, with Mr. Yi Yongfa as Chairman; its main responsibilities include reviewing financial statements, providing advice, and reviewing accounting standards, internal controls, and financial reporting procedures, and the Committee has reviewed the Group's unaudited condensed consolidated results - The Audit Committee comprises Ms. Yu Lin, a non-executive director, and Mr. Yi Yongfa (Chairman) and Mr. Pan Jiayang, two independent non-executive directors[98](index=98&type=chunk) - The Audit Committee's primary responsibilities include reviewing the Company's annual reports, financial statements, and half-yearly reports, providing advice and recommendations to the Board, and reviewing accounting standards, internal controls, and financial reporting procedures[98](index=98&type=chunk) - The Audit Committee has reviewed the Group's unaudited condensed consolidated results for the reporting period[99](index=99&type=chunk) [Compliance with Corporate Governance Code](index=41&type=section&id=Compliance%20with%20Corporate%20Governance%20Code) The Company complied with the Corporate Governance Code during the reporting period, except for the combined roles of Chairman and General Manager, and three independent non-executive directors serving over nine years, requiring new appointments to meet code requirements; the Board is seeking suitable candidates and has appointed Ms. Yu Lin as a member of the Nomination Committee - The roles of Chairman and General Manager are combined and held by Mr. Zhang Feng, which does not comply with Rule C.2.1 of the Corporate Governance Code[101](index=101&type=chunk) - Three independent non-executive directors have served for more than nine years, requiring the appointment of a new independent non-executive director to comply with Rule B.2.4(b) of the Corporate Governance Code[101](index=101&type=chunk) - The Board is seeking suitable candidates for new independent non-executive directors and has appointed Ms. Yu Lin, a non-executive director, as a member of the Nomination Committee[102](index=102&type=chunk)[103](index=103&type=chunk) [Events After Reporting Period](index=42&type=section&id=Events%20After%20Reporting%20Period) After the reporting period, the Board appointed Ms. Yu Lin as a member of the Nomination Committee on August 22, 2025, to address the revised Corporate Governance Code and GEM Listing Rules effective July 1, 2025; no other significant events affecting the Group occurred between the end of the reporting period and the date of this announcement - The Board appointed Ms. Yu Lin, a non-executive director, as a member of the Nomination Committee on August 22, 2025, to address the revised Corporate Governance Code and GEM Listing Rules effective July 1, 2025[103](index=103&type=chunk) - Other than the aforementioned disclosure, no other significant events affecting the Group occurred between the end of the reporting period and the date of this announcement[104](index=104&type=chunk)

深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* 1. 成員 2. 主席 * 僅供識別 1 1.1 提名委員會的成員須由董事會委任。 1.2 提名委員會最少須由三名成員組成，其中至少有一名必須為不同性別，且大部分成員須為獨立 非執行董事（「獨立非執行董事」）。 1.3 提名委員會每名成員的任命期限最長為三年，任期屆滿後可由董事會再次委任。 2.1 提名委員會主席須由董事會委任，並須由董事會主席或獨立非執行董事擔任。提名委員會主席 負責與董事會聯繫。 2.2 提名委員會主席應主持提名委員會會議。 2.3 若提名委員會主席缺席，出席會議的提名委員會其他成員應在他們當中選出一位成員主持提名 委員會會議。 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 提名委員會的職權範圍 本職權範圍於二零一二年三月十六日訂立，而經本公司董事（「董事」）會（「董事會」）批准之最新修訂本 則於二零二五年八月二十二日生效。 3. 秘書 4. 提名委員會會議的程序 4.1 法定人數 4.1.1 會議 ...